EICHORCondition: Urothelial Cancer · Sponsor: Astellas Pharma Korea, Inc.
Interested? Contact the study team ↓
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer. People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only. This study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study. Once a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.
This description comes directly from the study's public registry record.
Astellas Pharma Global Development, Inc. · 800-888-7704 · astellas.registration@astellas.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients who receive treatment with PADCEV Injection, according to the approved local label. Exclusion Criteria: * Patients with any contraindication for PADCEV Injection, according to the approved local label. * Patients who receive or are going to receive any investigational medicine during the observation period.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Site KR82001 | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
| Site KR82012 | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Site KR82008 | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Site KR82007 | Jeollanam-do, Jeollanam-do, South Korea | Completed |
| Site KR82013 | Jeonju, Jeonbuk-do, South Korea | Recruiting |
| Site KR82015 | Busan, South Korea | Active Not Recruiting |
| Site KR82010 | Busan, South Korea | Completed |
| Site KR82009 | Busan, South Korea | Active Not Recruiting |
| Site KR82016 | Busan, South Korea | Completed |
| Site KR82014 | Daegu, South Korea | Recruiting |
| Site KR82018 | Daejeon, South Korea | Recruiting |
| Site KR82004 | Incheon, South Korea | Active Not Recruiting |
+ 6 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06011954